Company
ENSC +7.15%Ensysce Biosciences, Inc.
Market Cap: $3.9 Million
USD as of Aug 2, 2026
$ENSC +7.15% $ENSC United States Healthcare Biotechnology US Healthcare US BiotechnologyEnsysce Biosciences, Inc. Market Capitalization Over Time
View HistoryEvolution of Ensysce Biosciences, Inc. market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.
Financials
| Last Financial Reports Date | None |
| Revenue TTM | $None |
| EBITDA | $None |
| Gross Profit TTM | $None |
| Profit Margin | % |
| Operating Margin | % |
| Quarterly Revenue Growth | % |
Stocks & Indexes
Ensysce Biosciences, Inc. main stocks and indexes inclusions.
$ENSCNASDAQ Composite